Aptivus (Tipranavir)
| Brand Name: |
Aptivus |
| Generic Name: |
Tipranavir |
| Adult Single Dose: |
Two 250-mg capsules or 5-mL oral solution, taken with two 100-mg capsules of ritonavir (twice a day) |
| Food & Liquid Restrictions: |
Can be taken with or without food. |
| Drug Class: |
PI |
|
|
|
The Basics
- FAQs About Tipranavir (Aptivus) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
- Tipranavir Patient Assistance Program (Regularly Updated)
Can't afford this medication? Click the link above to see if you qualify for the patient assistance program or call 1-800-556-8317.
From RxHope
- Tipranavir (Aptivus) (August 4, 2010)
To read PDF, click here.
From AIDS InfoNet
- Aptivus (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Aptivus (Tipranavir) (PDF) (June 2009)
From Boehringer Ingelheim
- An Overview of Aptivus (Tipranavir) (May 21, 2009)
From AIDSinfo
- Aptivus (Tipranavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Tipranavir: The First Nonpeptidic Protease Inhibitor (Winter 2003/2004)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Aptivus (Tipranavir): An In-Depth Look (Spring 2006)
Includes background information, study results, potential uses and side effects.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
News
- New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam (June 23, 2008)
From U.S. Food and Drug Administration
- U.S. FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy (June 23, 2005)
[Archived Article]
From Boehringer Ingelheim
- FDA Approval of Aptivus (Tipranavir) (June 23, 2005)
[Archived Article]
From U.S. Food and Drug Administration
- Tipranavir (Aptivus): Approval Cautiously Recommended (June 20, 2005)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Large Tipranavir Trials Open (January/February 2003)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tipranavir Patients May Experience Intracranial Hemorrhage, FDA Warns (June 30, 2006)
[Archived Article]
From U.S. Food and Drug Administration
Research
- Novel Mutations and Shifting Susceptibility to Darunavir and Tipranavir (September 15, 2010)
From National AIDS Treatment Advocacy Project
- New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference
- Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference
- Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Ritonavir-Boosted Tipranavir Increases ALT and AST Levels in HIV/Hepatitis-Coinfected Patients (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Tipranavir Heralds New Era for Treatment-Experienced Patients, Recent Studies Attest (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Ritonavir-Boosted Tipranavir Update at CROI 2005 (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
[Archived Article]
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group
- News on Developing Drugs and Drug Interactions (September/October 2004)
[Archived Article]
Updates on tipranavir, GS 9005 and the interaction between ddI and tenofovir.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tipranavir Reduces Concentrations of Other Protease Inhibitors (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Anti-HIV Therapy Update (July 2004)
[Archived Article]
A quick briefing on tipranavir, TMC-114, capravirine and D-D4FC.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Tipranavir Pharmacokinetics May Confine Its Use to Limited Rescue Role (June 2004)
[Archived Article]
In TAGline, from Treatment Action Group
- Drug Development News: Boehringer Ingelheim (May/June 2004)
[Archived Article]
An update on the protease inhibitor tipranavir and the NRTI alovudine, both for treatment-experienced patients.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- No Interactions Between Tipranavir/Ritonavir and Efavirenz, Tenofovir and AZT (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
[Archived Article]
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Tipranavir: Hare-Raising Comparison (April 2003)
[Archived Article]
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline Phenotypic Susceptibility to Tipranavir/Ritonavir Is Retained in Isolates From Patients With Multiple Protease Inhibitor Experience (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Anti-HIV Therapies: Tipranavir (January 2003)
[Archived Article]
From Project Inform
- Tipping the Scales at 500 mg -- Tipranavir! (December 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Tipranavir/Ritonavir: Derivation of Doses That Achieve Effective Plasma Concentrations Above the IC50 for Multiple PI-Resistant HIV-1 Viruses (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Resistance to Tipranavir is Uncommon in a Randomized Trial of Tipranavir/Ritonavir (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Tipranavir: The First Non-Peptidic Protease Inhibitor (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Safety and Efficacy of Tipranavir, a Non-Peptidic Protease Inhibitor, in Multiple PI-Failure Patients (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Study of Tipranavir for First-Line Treatment Ends Early (June 9, 2006)
Newly released results from an industry-sponsored study make it doubtful that tipranavir will ever be used as first-line therapy.
From Boehringer Ingelheim
|
|
Advertisement
|
Email
Glossary
